Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/29/2007US20070071819 Multiple unit modified release compositions of carbamazepine and process for their preparation
03/29/2007US20070071818 Effervescent formulations comprising apomorphine
03/29/2007US20070071815 Oral formulation of creatine derivatives and method of manufacturing same
03/29/2007US20070071814 Vaginal tablets comprising misoprostol and methods of making and using the same
03/29/2007US20070071813 Novel dosage formulation
03/29/2007US20070071812 Pharmaceutical composition containing fenofibrate and method for the preparation thereof
03/29/2007US20070071811 Stable combinations of amlodipine besylate and benazepril hydrochloride
03/29/2007US20070071810 Additive for tablets
03/29/2007US20070071809 Ginger containing compositions to control pain
03/29/2007US20070071806 Tansmucosal drug delivery system
03/29/2007US20070071805 Treatment of inflammation and vascular abnormalities of the eye
03/29/2007US20070071803 Dermal penetration enhancers and drug delivery systems involving same
03/29/2007US20070071802 Topical anesthetic for dental procedures
03/29/2007US20070071794 Drugs for treating diabetes
03/29/2007US20070071779 Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
03/29/2007US20070071777 Oil emulsion for postnatal hormone substitution
03/29/2007US20070071770 Recombinant MVA virus, and the use thereof
03/29/2007US20070071769 Recombinant MVA virus, and the use thereof
03/29/2007US20070071765 Compositions for Immunotherapy and Uses Thereof
03/29/2007US20070071761 treatment of colon tumor with a mixture of chemotherapeutic agent selected from cyclophosphamide or doxorubicin and an antigen binding fragment; synergistic potentiation; rheumatoid arthritis
03/29/2007US20070071756 Delivery of an agent to ameliorate inflammation
03/29/2007US20070071754 Method to ameliorate inflammation
03/29/2007US20070071752 Sphingosine kinase enzyme
03/29/2007US20070071749 Using cocktail comprising endothelial growth factor specific immunoglobulin and gemcitabine to treat and/or prevent pancreatic cancer
03/29/2007US20070071748 Treatment with anti-vegf antibodies
03/29/2007US20070071747 Use of TNFalpha inhibitor for treatment of erosive polyarthritis
03/29/2007US20070071731 Promotion Of Neurogenesis Of Endogenous And Transplanted Human Neural Stem Cells
03/29/2007US20070071730 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
03/29/2007US20070071720 Method of treating hepatitis B viral infection
03/29/2007US20070071718 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of leukemia; immunotherapy
03/29/2007US20070071715 Methods and compositions for phosphate binding
03/29/2007US20070071713 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents
03/29/2007US20070071712 biomimetics; cavity has affinity for glucose
03/29/2007US20070071710 Extract of vanilla planifolia
03/29/2007US20070071705 Topical anti-microbial compositions
03/29/2007US20070071704 Silicone-in-water emulsion compositions containing retinoids
03/29/2007US20070071699 Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
03/29/2007US20070071692 Aerosol powder formulation
03/29/2007US20070071691 Composition
03/29/2007US20070071690 Dry powder formulations
03/29/2007US20070071689 Advantageous combination for inhalation of nacystelyn and bronchodilators
03/29/2007US20070071688 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
03/29/2007US20070071687 Intranasal benzodiazepine compositions
03/29/2007US20070071686 Liquid preparation containing tobramycin
03/29/2007US20070071683 Ultrasonic concentration of carrier particles
03/29/2007DE20321405U1 Wirkstoffkonzentrate Active ingredient concentrates
03/29/2007DE202006013518U1 Mittel zur Behandlung von neuroendokrinen gesundheitlichen Störungen Agents for the treatment of health disorders neuroendocrine
03/29/2007DE102005058978A1 Wund- und Schleimhautdesinfektionsmittel Wound and mucous membrane disinfectant
03/29/2007DE102005045989A1 Powder base, useful for e.g. protecting the skin from disorders, comprises e.g. protective material, mineral pigment, different organic materials, urea, antimicrobial-, antiseptic-, anitinflammatory- and itch protective- agents
03/29/2007DE102005045829A1 Mittel enthaltend langkettige Alkohole zur Suppression der Konzentrationen des C-reaktiven Proteins (CRP) im menschlichen Blut Compositions comprising long-chain alcohols for the suppression of the concentrations of C-reactive protein (CRP) in human blood
03/29/2007DE102005045518A1 New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
03/29/2007DE102005045146A1 Antimicrobial preparation useful for treating e.g. wound, eczema and vaginal infections comprises octenidine dihydrochloride encapsulated in liposomes
03/29/2007DE102005045145A1 Verwendung von Octenidindihydrochlorid in halbfesten Zubereitungen Use of octenidine in semi-solid preparations
03/29/2007DE102005044156A1 Substituierte Acetophenonderivate Substituted acetophenone
03/29/2007DE102005017326A1 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Tetrahydronaphthalene derivatives, processes for their preparation and their use as anti-inflammatories
03/29/2007DE10125882B4 Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus Medicament comprising ambroxol, its salts and / or prodrugs together with α-lipoic acid in the context of the treatment of diabetes mellitus
03/29/2007CA2800945A1 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
03/29/2007CA2624420A1 Vitamin d derivatives for the treatment of type i diabetes
03/29/2007CA2623803A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
03/29/2007CA2623772A1 Modulation of glucocorticoid receptor expression
03/29/2007CA2623762A1 Modulation of glucagon receptor expression
03/29/2007CA2623590A1 A preparation for treatment of non-infectious inflammatory intestinal diseases
03/29/2007CA2623472A1 Use of inhibitors of the na+/h+ exchanger, subtype 5 (nhe5), to improve memory retention
03/29/2007CA2623462A1 Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
03/29/2007CA2623391A1 Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
03/29/2007CA2623351A1 Antiviral therapy with carbohydrate binding agents
03/29/2007CA2623345A1 Fulvestrant formulation
03/29/2007CA2623326A1 Amino-alkyl-amide derivatives as ccr3 receptor ligands
03/29/2007CA2623317A1 Amino-alkyl-amide derivatives as ccr3 receptor liquids
03/29/2007CA2623312A1 Amino-alkyl-amide derivatives as ccr3 receptor ligands
03/29/2007CA2623304A1 Medicine, food and drink or feed containing sphingomyelin
03/29/2007CA2623281A1 Composition comprising a nsaid and paracetamol
03/29/2007CA2623205A1 Modulation of osteoclast differentiation
03/29/2007CA2623203A1 Methods for treating viral infections using polyamine analogs
03/29/2007CA2623184A1 Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
03/29/2007CA2623153A1 The use of sirnas in organ storage/reperfusion solutions
03/29/2007CA2623117A1 Novel crystal forms of irinotecan hydrochloride
03/29/2007CA2623092A1 2-aminoalcohols for the treatment of neurodegenerative diseases
03/29/2007CA2623025A1 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
03/29/2007CA2622960A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment
03/29/2007CA2622912A1 Cytotoxin compounds and methods of isolation
03/29/2007CA2622870A1 Dosage forms and methods of treatment using a tyrosine kinase inhibitor
03/29/2007CA2622758A1 Nanoparticulate aripiprazole formulations
03/29/2007CA2622741A1 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
03/29/2007CA2622708A1 Anesthesia induction and maintenance drug
03/29/2007CA2622704A1 Highly concentrated pourable aqueous solutions of potassium ibuprofen their preparation and their uses
03/29/2007CA2622698A1 Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
03/29/2007CA2622693A1 Sachet formulation for amine polymers
03/29/2007CA2622674A1 Palmarumycin based inhibitors of thioredoxin and methods of using same
03/29/2007CA2622629A1 Aptamers as agonists
03/29/2007CA2622592A1 Benzodiazepine derivatives for treating hepatitis c infection
03/29/2007CA2622523A1 Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
03/29/2007CA2622461A1 Chemo-immunotherapy method
03/29/2007CA2622086A1 Sulphonamide derivatives
03/29/2007CA2621720A1 Carbazole derivatives
03/29/2007CA2621062A1 Alkyl sulfoxide quinolines as nk-3 receptor ligands
03/29/2007CA2621059A1 Stabilized protease composition
03/29/2007CA2620675A1 Metallo-.beta.-lactamase inhibitors
03/29/2007CA2620235A1 Association of .beta.3 receptor agonist and monoamine reuptake inhibitors, pharmaceutical composition containing same and therapeutic use thereof
03/29/2007CA2619093A1 Modulators of metabolism and the treatment of disorders related thereto